[1]李秀云,朱艳,邓爱军.Ranibizumab治疗糖尿病性黄斑水肿短期疗效观察[J].眼科新进展,2016,36(1):067-69.[doi:10.13389/j.cnki.rao.2016.0019]
　LI Xiu-Yun,ZHU Yan,DENG Ai-Jun.Short-term efficacy of Ranibizumab for diabetic macular edema[J].Recent Advances in Ophthalmology,2016,36(1):067-69.[doi:10.13389/j.cnki.rao.2016.0019]
点击复制

Ranibizumab治疗糖尿病性黄斑水肿短期疗效观察
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
36卷
期数:
2016年1期
页码:
067-69
栏目:
应用研究
出版日期:
2016-01-05

文章信息/Info

Title:
Short-term efficacy of Ranibizumab for diabetic macular edema
作者:
李秀云; 朱艳; 邓爱军
261035　山东省潍坊市，潍坊医学院附属医院眼科
Author(s):
LI Xiu-Yun; ZHU Yan; DENG Ai-Jun
Department of Ophthatmology,Affiliated Hospital to Weifang Medical College,Weifang 261035,Shandong Province．China
关键词:
Ranibizumab; 糖尿病性黄斑水肿; 光学相干断层扫描
Keywords:
Ranibizumab ;  diabetic macular edema;  optical coherence tomography
DOI:
10.13389/j.cnki.rao.2016.0019
文献标志码:
A
摘要:
目的　观察玻璃体内注射Ｒａｎｉｂｉｚｕｍａｂ治疗糖尿病性黄斑水肿的短期疗效。方法　在我院诊断为糖尿病性黄斑水肿患者３４例（４６眼），应用药物治疗、激光治疗或手术治疗，黄斑水肿无改善或持续加重，应用Ｒａｎｉｂｉｚｕｍａｂ０．５ｍｇ（０．０５ｍＬ）玻璃体内注射，术后随访１２个月，根据眼底、视力及ＯＣＴ检查决定是否再次注射。结果　所有患者玻璃体内注射Ｒａｎｉｂｉｚｕｍａｂ无局部和全身并发症。每眼注射次数为１～４次，平均２．３９次，重复注射时间为注射后１．０～１．５个月。４６眼注射后１２个月视力不同程度提高者４４眼，２眼保持不变，注射后７ｄ、１个月、６个月、１２个月最佳矫正视力分别提高２．３２个、３．４７个、５．３４个和６．２５个字母。ＯＣＴ检查结果显示注射Ｒａｎｉｂｉｚｕｍａｂ后黄斑区视网膜水肿明显减轻，首次注射后７ｄ、１个月、６个月、１２个月黄斑中心视网膜厚度值分别为（４２５±３８）μｍ、（３７２±４１）μｍ、（２９４±３２）μｍ和（２７６±２５）μｍ，与注射前（６４７±４２）μｍ相比差异均有统计学意义（均为Ｐ＜０．０５）。结论　对于糖尿病性黄斑水肿患者，玻璃体内注射Ｒａｎｉｂｉｚｕｍａｂ具有很好的安全性和有效性，可明显促进黄斑水肿吸收，提高视力，ＯＣＴ检查可作为评价是否需要再次注射的标准。
Abstract:
Objective To study the short-time efficacy of intravitreal injection of Ranibizumab in patients with diabetic macular edema. Methods Thirty-four patients (46 eyes) with diabetic macular edema who had medicine.laser coagulation or operation before were studied. They received intravitreal injection of 0. 05 mL ( 0. 5 mg) Ranibizumab once. Further injection was required according to patients ’ visual acuity or OCT results at 12 months follow-up time. Results There was no local or systemic complication in all patients. Each eye received I - 4 injections ( mean 2. 39) . Further injection was performed at l. 0 - 1. 5 months after first injection. The best corrected visual acuity at 7 days,l month .6 months and 12 months after injection increased 3. 32 letters. 3. 47 letters .5. 34 letters and 6. 25 letters , respectively. The mean central retinal thickness at 7 days , I month,6 months and 12 months after injection were ( 425 + 38) ym, ( 372 + 41 ) p m, ( 294 + 32 ) ym , ( 276 + 25 ) ym , respectively , there were sigruficant differences compared with before injection ( 647 +42) ym ( all P < 0. 05 ) . Conclusion Intravitreal injection of Ranibizumab is effective and safe for diabetic macular edema . can improve the visual acuity and promote the absorption of macular edema. OCT examination is one of important manners for determining the further injection.

相似文献/References:

[1]麻南 李丹 高付林 胡莲娜.玻璃体内注射贝伐单抗和贝伐单抗/曲安奈德联合用药治疗糖尿病性黄斑水肿疗效及安全性差异的荟萃分析[J].眼科新进展,2012,32(6):000.
[2]陆秉文 吴星伟.视网膜静脉阻塞黄斑水肿患者玻璃体内注射ranibi-zumab后视野变化[J].眼科新进展,2013,33(12):000.
[3]陆秉文 吴星伟. 苦碟子注射液联合光动力疗法与玻璃体内注射Ranibizumab治疗渗出型年龄相关性黄斑变性[J].眼科新进展,2014,34(3):268.
[4]王玲,生侠,吴清静,等.红外线及自发荧光影像在糖尿病性黄斑水肿诊断中的价值[J].眼科新进展,2014,34(8):754.[doi:10.13389/j.cnki.rao.2014.0207]
　WANG Ling,SHENG Xia,WU Qing-Jing,et al.Value of infrared ray and auto fluorescence in diagnosis of diabetic macular edema[J].Recent Advances in Ophthalmology,2014,34(1):754.[doi:10.13389/j.cnki.rao.2014.0207]
[5]陆秉文,吴星伟. Ranibizumab玻璃体内注射治疗病理性近视脉络膜新生血管研究进展[J].眼科新进展,2014,34(9):897.[doi:10.13389/j.cnki.rao.2014.0248]
[6]杨宇,田敏,吕红彬. 糖尿病视网膜病变的治疗进展[J].眼科新进展,2015,35(5):497.[doi:10.13389/j.cnki.rao.2015.0136]
　YANG Yu,TIAN Min,LV Hong-Bin. Recent advances in treatment of diabetic retinopathy[J].Recent Advances in Ophthalmology,2015,35(1):497.[doi:10.13389/j.cnki.rao.2015.0136]
[7]李素华,高永峰. 比较单独黄斑局灶/格栅样光凝术和联合雷珠单抗治疗糖尿病性黄斑水肿的疗效[J].眼科新进展,2015,35(6):566.[doi:10.13389/j.cnki.rao.2015.0153]
　LI Su-Hua,GAO Yong-Feng. Efficacy of macular focal / grid photocoagulation combined with ranibizumab for diabetic macular edema[J].Recent Advances in Ophthalmology,2015,35(1):566.[doi:10.13389/j.cnki.rao.2015.0153]
[8]陈小红,王云鹏,陈梅珠. VEGF在糖尿病性视网膜病变发病机制中的作用及抗VEGF治疗新进展[J].眼科新进展,2015,35(7):692.[doi:10.13389/j.cnki.rao.2015.0190]
　CHEN Xiao-Hong,WANG Yun-Peng,CHEN Mei-Zhu. Role of VEGF in pathogenesis of diabetic retinopathy and anti-VEGF therapy[J].Recent Advances in Ophthalmology,2015,35(1):692.[doi:10.13389/j.cnki.rao.2015.0190]
[9]夏风杰,闫峰,陆燕,等.糖尿病性黄斑水肿临床治疗进展[J].眼科新进展,2015,35(10):985.[doi:10.13389/j.cnki.rao.2015.0270]
　XIA Feng-Jie,YAN Feng,LU Yan,et al.Clinical treatment advances in diabetic macular edema[J].Recent Advances in Ophthalmology,2015,35(1):985.[doi:10.13389/j.cnki.rao.2015.0270]
[10]陈素芳,李亨辉,邵毅,等.非诺贝特在糖尿病性黄斑水肿中的临床研究[J].眼科新进展,2016,36(2):136.[doi:10.13389/j.cnki.rao.2016.0037]
　CHEN Su-Fang,LI Heng-Hui,SHAO Yi,et al.Clinical study of fenofibrate in diabetic macular edema[J].Recent Advances in Ophthalmology,2016,36(1):136.[doi:10.13389/j.cnki.rao.2016.0037]

备注/Memo

备注/Memo:
山东省教育厅项目资助（编号：Ｊ１０ＬＦ６）；潍坊医学院附属医院青年基金项目
更新日期/Last Update: 2016-01-04